The incidence of esophageal adenocarcinoma (EAC) is rising rapidly in Western countries, and effective chemoprevention for this malignancy is lacking. Endoscopic surveillance of patients with Barrett's esophagus is currently employed to diagnose EAC at earlier stages, but this strategy has several limitations. Non-steroidal anti-inflammatory drugs and proton pump inhibitors are the most promising agents for prevention of EAC, and a randomized controlled trial of aspirin and esomeprazole is ongoing. Other agents under investigation include green tea, berries, and antioxidants. Cost-effectiveness analyses have shown that chemopreventive agents need to be highly effective at preventing EAC in order to have benefit beyond endoscopic surveillance.
Abdalla, S.I., Lao-Sirieix, P., Novelli, M.R., Lovat, L.B., Sanderson, I.R. and Fitzgerald, R.C. (2004) Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res10: 4784-4792.
2.
Abdalla, S.I., Sanderson, I.R. and Fitzgerald, R.C. (2005) Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells . Carcinogenesis26: 1627-1633.
3.
Anderson, L.A., Johnston, B.T., Watson, R.G., Murphy, S.J., Ferguson, H.R., Comber, H. et al. (2006) Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res66: 4975-4982.
4.
Arber, N., Eagle, C.J., Spicak, J., Racz, I., Dite, P., Hajer, J. et al. (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med355: 885-895.
5.
Bardou, M., Barkun, A.N., Ghosn, J., Hudson, M. and Rahme, E. (2004) Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol2: 880-887.
6.
Baron, J.A., Cole, B.F., Sandler, R.S., Haile, R.W., Ahnen, D., Bresalier, R. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med348: 891-899.
7.
Baron, J.A., Sandler, R.S., Haile, R.W., Mandel, J.S., Mott, L.A. and Greenberg, E.R. (1998) Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst90: 57-62.
8.
Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K. et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med355: 873-884.
9.
Buttar, N.S., Wang, K.K., Anderson, M.A., Dierkhising, R.A., Pacifico, R.J., Krishnadath, K.K. et al. (2002a) The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst94: 422-429.
10.
Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A. et al. (2002b) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology122: 1101-1112.
11.
Cabrera, C., Artacho, R. and Gimenez, R. (2006) Beneficial effects of green tea-a review. J Am Coll Nutr25: 79-99.
12.
Chandanos, E., Lindblad, M., Jia, C., Rubio, C.A., Ye, W. and Lagergren, J. (2006) Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer95: 118-122.
13.
Chang, C.L., Hong, E., Lao-Sirieix, P. and Fitzgerald, R.C. (2007a) A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma. Oncogene (2008) 27: 2951-60.
14.
Chang, C.L., Lao-Sirieix, P., Save, V., De La Cueva Mendez, G., Laskey, R. and Fitzgerald, R.C. (2007b) Retinoic acid-induced glandular differentiation of the oesophagus. Gut56: 906-917.
15.
Chen, H., Tucker, K.L., Graubard, B.I., Heineman, E.F., Markin, R.S., Potischman, N.A. et al. (2002) Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer42: 33-40.
16.
Chen, T., Hwang, H., Rose, M.E., Nines, R.G. and Stoner, G.D. (2006) Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamineinduced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res66: 2853-2859.
17.
Cheng, K.K., Sharp, L., McKinney, P.A., Logan, R.F., Chilvers, C.E., Cook-Mozaffari, P. et al. (2000) A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer83: 127-132.
18.
Choi, S.W. and Mason J.B. (2000) Folate and carcinogenesis: an integrated scheme . J Nutr130: 129-132.
19.
Chow, W.H., Finkle, W.D., McLaughlin, J.K., Frankl, H., Ziel, H.K. and Fraumeni Jr, J.F. (1995) The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. Jama274: 474-477.
20.
Clemons, N.J., McColl, K.E. and Fitzgerald, R.C. (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology133: 1198-1209.
21.
Cole, B.F., Baron, J.A., Sandler, R.S., Haile, R.W., Ahnen, D.J., Bresalier, R.S. et al. (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. Jama297: 2351-2359.
22.
Cooper, B.T., Chapman, W., Neumann, C.S. and Gearty, J.C. (2006) Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther23: 727-733.
23.
Corley, D.A., Kerlikowske, K., Verma, R. and Buffler, P. (2003) Protective association of aspirin/ NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology124: 47-56.
24.
Corley, D.A., Levin, T.R., Habel, L.A., Weiss, N.S. and Buffler, P.A. (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology122: 633-640.
25.
D'Alessandro, T., Prasain, J., Benton, M.R., Botting, N., Moore, R., Darley-Usmar, V. et al. (2003) Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J Nutr133.
26.
Duan, L., Wu, A.H., Sullivan-Halley, J. and Bernstein, L. (2008) Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev17: 126-134.
27.
El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A. and Sampliner, R.E. (2004a) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol99: 1877-1883.
28.
El-Serag, H.B., Petersen, N.J., Carter, J., Graham, D.Y., Richardson, P., Genta, R.M. et al. (2004b) Gastroesophageal reflux among different racial groups in the United States. Gastroenterology126: 1692-1699.
29.
Farhadi, A., Fields, J., Banan, A. and Keshavarzian, A. (2002) Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer?Am J Gastroenterol97: 22-26.
30.
Farrow, D.C., Vaughan, T.L., Hansten, P.D., Stanford, J.L., Risch, H.A., Gammon, M.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev7: 97-102.
31.
Farrow, D.C., Vaughan, T.L., Sweeney, C., Gammon, M.D., Chow, W.H., Risch, H.A. et al. (2000) Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control11: 231-238.
32.
Fass, R., Quan, S.F., O'Connor, G.T., Ervin, A. and Iber, C. (2005) Predictors of heartburn during sleep in a large prospective cohort study. Chest127: 1658-1666.
33.
Feagins, L.A., Zhang, H.Y., Hormi-Carver, K., Quinones, M.H., Thomas, D., Zhang, X. et al. (2007) Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol102: 10-20.
34.
Federico, A., Morgillo, F., Tuccillo, C., Ciardiello, F. and Loguercio, C. (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer121: 2381-2386.
35.
Ferrario, C.M. and Strawn, W.B. (2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol98: 121-128.
36.
Fiorucci, S., Santucci, L., Farroni, F., Pelli, M.A. and Morelli, A. (1989) Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. Am J Gastroenterol84: 1263-1267.
37.
Fitzgerald, R.C., Omary, M.B. and Triadafilopoulos, G. (1996) Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model . J Clin Invest98: 2120-2128.
38.
Freedman, N.D., Park, Y., Subar, A.F., Hollenbeck, A.R., Leitzmann, M.F., Schatzkin, A. et al. (2007) Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer121: 2753-2760.
39.
Funkhouser, E.M. and Sharp, G.B. (1995) Aspirin and reduced risk of esophageal carcinoma . Cancer76: 1116-1119.
40.
Gammon, M.D., Terry, M.B., Arber, N., Chow, W.H., Risch, H.A., Vaughan, T.L. et al. (2004) Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev13: 34-39.
41.
Garcia Rodriguez, L.A., Lagergren, J. and Lindblad, M. (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut55: 1538-1544.
42.
Georgopoulos, S.D., Polymeros, D., Triantafyllou, K., Spiliadi, C., Mentis, A., Karamanolis, D.G. et al. (2006) Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion74: 42-46.
Giovannucci, E., Rimm, E.B., Ascherio, A., Stampfer, M.J., Colditz, G.A. and Willett, W.C. (1995) Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst87: 265-273.
45.
Giovannucci, E., Stampfer, M.J., Colditz, G.A., Hunter, D.J., Fuchs, C., Rosner, B.A. et al. (1998) Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med129: 517-524.
46.
Gonzalez, C.A., Pera, G., Agudo, A., Bueno-de-Mesquita, H.B., Ceroti, M., Boeing, H. et al. (2006) Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer118: 2559-2566.
47.
Haigh, C.R., Attwood, S.E., Thompson, D.G., Jankowski, J.A., Kirton, C.M., Pritchard, D.M. et al. (2003) Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology124: 615-625.
48.
Hao, Y., Sood, S., Triadafilopoulos, G., Kim, J.H., Wang, Z., Sahbaie, P. et al. (2007) Gene expression changes associated with Barrett's esophagus and Barrett's-associated adenocarcinoma cell lines after acid or bile salt exposure. BMC Gastroenterol7(24): 1-10.
49.
Harris, J.C., Clarke, P.A., Awan, A., Jankowski, J. and Watson, S.A. (2004) An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res64: 1915-1919.
50.
Heath, E.I., Canto, M.I., Piantadosi, S., Montgomery, E., Weinstein, W.M., Herman, J.G. et al. (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst99: 545-557.
51.
Hermann, B., Li, Y., Ray, M.B., Wo, J.M. and Martin, R.C.II. (2005) Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus . Arch Surg140: 1204-1209.
52.
Hillman, L.C., Chiragakis, L., Shadbolt, B., Kaye, G.L. and Clarke, A.C. (2004) Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust180: 387-391.
53.
Hillman, L.C., Chiragakis, L., Shadbolt, B., Kaye, G.L. and Clarke, A.C. (2008) Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus . Aliment Pharmacol Ther27: 321-326.
54.
Hormi-Carver, K., Feagins, L.A., Spechler, S.J. and Souza, R.F. (2007) All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett's cells. Am J Physiol Gastrointest Liver Physiol292: G18-27.
55.
Howe, L.R. and Dannenberg, A.J. (2002) A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol29: 111-119.
56.
Hur, C., Nishioka, N.S. and Gazelle, G.S. (2004) Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst96: 316-325.
57.
Iijima, K., Grant, J., McElroy, K., Fyfe, V., Preston, T. and McColl, K.E. (2003) Novel mechanism of nitrosative stress from dietary nitrate with relevance to gastro-oesophageal junction cancers. Carcinogenesis24: 1951-1960.
58.
Jankowski, J. and Moayyedi, P. (2004) Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst96: 885-887.
59.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M.J. (2007) Cancer statistics, 2007. CA Cancer J Clin57: 43-66.
60.
Katz, P.O., Koch, F.K., Ballard, E.D., Bagin, R.G., Gautille, T.C., Checani, G.C. et al. (2007) Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther25: 197-205.
61.
Katz, P.O., Scheiman, J.M. and Barkun, A.N. (2006) Review article: acid-related disease-what are the unmet clinical needs?Aliment Pharmacol Ther23 Suppl 2: 9-22.
62.
Kaur, B.S., Khamnehei, N., Iravani, M., Namburu, S.S., Lin, O. and Triadafilopoulos, G. (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus . Gastroenterology123: 60-67.
63.
Koop, H., Klein, M. and Arnold, R. (1990) Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther4: 131-138.
64.
Kresty, L.A., Frankel, W.L., Hammond, C.D., Baird, M.E., Mele, J.M., Stoner, G.D. et al. (2006) Transitioning from preclinical to clinical chemopreventive assessments of lyophilized black raspberries: interim results show berries modulate markers of oxidative stress in Barrett's esophagus patients . Nutr Cancer54: 148-156.
65.
Kristal, A.R., Blount, P.L., Schenk, J.M., Sanchez, C.A., Rabinovitch, P.S., Odze, R.D. et al. (2005) Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev14: 2377-2383.
66.
Kubo, A. and Corley, D.A. (2002) Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer95: 2096-2102.
67.
Kumagai, H., Mukaisho, K., Sugihara, H., Miwa, K., Yamamoto, G. and Hattori, T. (2004) Thioproline inhibits development of esophageal adenocarcinoma induced by gastroduodenal reflux in rats. Carcinogenesis25: 723-727.
68.
Kusyk, C.J., McNiel, N.O. and Johnson, L.R. (1986) Stimulation of growth of a colon cancer cell line by gastrin. Am J Physiol251: G597-601.
69.
Lagergren, J., Bergstrom, R., Lindgren, A. and Nyren, O. (1999a) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med340: 825-831.
70.
Lagergren, J., Bergstrom, R. and Nyren, O. (1999b) Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med130: 883-890.
71.
Lagergren, J. and Jansson, C. (2005) Sex hormones and oesophageal adenocarcinoma: influence of childbearing? Br J Cancer93: 859-861.
72.
Lagergren, J. and Nyren, O. (1998) Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev7: 913-915.
73.
Lagergren, J., Viklund, P. and Jansson, C. (2006) Carbonated soft drinks and risk of esophageal adenocarcinoma: a population-based case-control study. J Natl Cancer Inst98: 1158-1161.
74.
Lao-Sirieix, P., Roy, A., Worrall, C., Vowler, S.L., Gardiner, S. and Fitzgerald, R.C. (2006) Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev15: 288-293.
75.
Larsson, S.C., Giovannucci, E. and Wolk, A. (2005) A prospective study of dietary folate intake and risk of colorectal cancer: modification by caffeine intake and cigarette smoking . Cancer Epidemiol Biomarkers Prev14: 740-743.
76.
Larsson, S.C., Giovannucci, E. and Wolk, A. (2006) Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology131: 1271-1283.
77.
Lindblad, M., Garcia Rodriguez, L.A., Chandanos, E. and Lagergren, J. (2006) Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer94: 136-141.
78.
Lord, R.V., Tsai, P.I., Danenberg, K.D., Peters, J.H., Demeester, T.R., Tsao-Wei, D.D. et al. (2001) Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery129: 267-276.
79.
Martin, R.C., Liu, Q., Wo, J.M., Ray, M.B. and Li, Y. (2007) Chemoprevention of carcinogenic progression to esophageal adenocarcinoma by the manganese superoxide dismutase supplementation . Clin Cancer Res13: 5176-5182.
80.
Masuda, M., Suzui, M., Lim, J.T. and Weinstein, I.B. (2003) Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res9: 3486-3491.
81.
Masuda, M., Suzui, M. and Weinstein, I.B. (2001) Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines . Clin Cancer Res7: 4220-4229.
82.
Mayne, S.T., Risch, H.A., Dubrow, R., Chow, W.H., Gammon, M.D., Vaughan, T.L. et al. (2006) Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst98: 72-75.
83.
Mayne, S.T., Risch, H.A., Dubrow, R., Chow, W.H., Gammon, M.D., Vaughan, T.L. et al. (2001) Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev10: 1055-1062.
84.
Mehta, S., Boddy, A., Johnson, I.T. and Rhodes, M. (2006) Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther24: 1321-1331.
85.
Morgan, C., Alazawi, W., Sirieix, P., Freeman, T., Coleman, N. and Fitzgerald, R. (2004) In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol99: 218-224.
86.
Morris, C.D., Armstrong, G.R., Bigley, G., Green, H. and Attwood, S.E. (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol96: 990-996.
87.
Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A. et al. (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med334: 1150-1155.
88.
Ouatu-Lascar, R., Fitzgerald, R.C. and Triadafilopoulos, G. (1999) Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology117: 327-335.
89.
Piazuelo, E., Cebrian, C., Escartin, A., Jimenez, P., Soteras, F., Ortego, J. et al. (2005) Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J Gastroenterol11: 7436-7443.
90.
Rex, D.K., Cummings, O.W., Shaw, M., Cumings, M.D., Wong, R.K., Vasudeva, R.S. et al. (2003) Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology125: 1670-1677.
91.
Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E. et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology129: 1825-1831.
92.
Saffari, Y. and Sadrzadeh, S.M. (2004) Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sci74: 1513-1518.
93.
Sandler, R.S., Halabi, S., Baron, J.A., Budinger, S., Paskett, E., Keresztes, R. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med348: 883-890.
94.
Sasaki, S., Miwa, K., Fujimura, T., Oba, M., Miyashita, T. and Kinami, S. (2007) Ingestion of thioproline suppresses rat esophageal adenocarcinogenesis caused by duodenogastroesophageal reflux. Oncol Rep18: 1443-1449.
95.
Schlansky, B., Dimarino Jr, A.J., Loren, D., Infantolino, A., Kowalski, T. and Cohen, S. (2006) A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther23: 587-593.
96.
Shaheen, N. and Ransohoff, D.F. (2002) Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. Jama287: 1972-1981.
97.
Shirvani, V.N., Ouatu-Lascar, R., Kaur, B.S., Omary, M.B. and Triadafilopoulos, G. (2000) Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology118: 487-496.
98.
Sihvo, E.I., Salminen, J.T., Rantanen, T.K., Ramo, O.J., Ahotupa, M., Farkkila, M. et al. (2002) Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer102: 551-555.
99.
Sjoberg, T., Garcia Rodriguez, L.A. and Lindblad, M. (2007) Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol5: 1160-1166e1.
100.
Smith, J.P. and Solomon, T.E. (1988) Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology95: 1541-1548.
101.
Sobhani, I., Lehy, T., Laurent-Puig, P., Cadiot, G., Ruszniewski, P. and Mignon, M. (1993) Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology105: 22-30.
102.
Soler, M., Bosetti, C., Franceschi, S., Negri, E., Zambon, P., Talamini, R. et al. (2001) Fiber intake and the risk of oral, pharyngeal and esophageal cancer. Int J Cancer91: 283-287.
103.
Sonnenberg, A. and Fennerty, M.B. (2003) Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology124: 1758-1766.
104.
Souza, R.F., Shewmake, K., Beer, D.G., Cryer, B. and Spechler, S.J. (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res60: 5767-5772.
105.
Souza, R.F., Shewmake, K., Pearson, S., Sarosi Jr, G.A., Feagins, L.A., Ramirez, R.D. et al. (2004) Acid increases proliferation via ERK and p38 MAPKmediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol287: G743-G748.
106.
Souza, R.F., Shewmake, K., Terada, L.S. and Spechler, S.J. (2002) Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology122: 299-307.
Stoner, G.D., Wang, L.S., Zikri, N., Chen, T., Hecht, S.S., Huang, C. et al. (2007) Cancer prevention with freeze-dried berries and berry components. Semin Cancer Biol17: 403-410.
109.
Sun, C.L., Yuan, J.M., Koh, W.P. and Yu, M.C. (2006) Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis27: 1301-1309.
110.
Sun, S.Y. and Lotan, R. (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol41: 41-55.
111.
Terry, P., Lagergren, J., Hansen, H., Wolk, A. and Nyren, O. (2001) Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev10: 365-369.
112.
Terry, P., Lagergren, J., Ye, W., Nyren, O. and Wolk, A. (2000) Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer87: 750-754.
113.
Thorburn, C.M., Friedman, G.D., Dickinson, C.J., Vogelman, J.H., Orentreich, N. and Parsonnet, J. (1998) Gastrin and colorectal cancer: a prospective study . Gastroenterology115: 275-280.
114.
Tsuda, M. and Kurashima, Y. (1991) Nitrite-trapping capacity of thioproline in the human body. IARC Sci Publ00: 123-128.
115.
Umansky, M., Yasui, W., Hallak, A., Brill, S., Shapira, I., Halpern, Z. et al. (2001) Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene20: 7987-7991.
116.
Sandick, J.W., van Lanschot, J.J., Kuiken, B.W., Tytgat, G.N., Offerhaus, G.J. and Obertop, H. (1998) Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma . Gut43: 216-222.
117.
Vaughan, T.L., Dong, L.M., Blount, P.L., Ayub, K., Odze, R.D., Sanchez, C.A. et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study . Lancet Oncol6: 945-952.
118.
Vizcaino, A.P., Moreno, V., Lambert, R. and Parkin, D.M. (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer99: 860-868.
119.
Wilson, K.T., Fu, S., Ramanujam, K.S. and Meltzer, S.J. (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas . Cancer Res58: 2929-2934.
120.
Wright, T.A., Gray, M.R., Morris, A.I., Gilmore, I.T., Ellis, A., Smart, H.L. et al. (1996) Cost effectiveness of detecting Barrett's cancer. Gut39: 574-579.
121.
Yang, G., Shu, X.O., Li, H., Chow, W.H., Ji, B.T., Zhang, X. et al. (2007) Prospective cohort study of green tea consumption and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev16: 1219-1223.
122.
Zhang, F., Altorki, N.K., Wu, Y.C., Soslow, R.A., Subbaramaiah, K. and Dannenberg, A.J. (2001) Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology121: 1391-1399.
123.
Zhang, H.Y., Zhang, X., Hormi-Carver, K., Feagins, L.A., Spechler, S.J. and Souza, R.F. (2007) In non-neoplastic Barrett's epithelial cells, acid exerts early antiproliferative effects through activation of the Chk2 pathway . Cancer Res67: 8580-8587.
